18F-metafluorobenzylguanidine (18F-MFBG) PET/CT in Neuroblastoma. The First experience In Russia: Comparison with 123I-metaiodobenzylguanidine (123I-MIBG) Scintigraphy
https://doi.org/10.37174/2587-7593-2025-8-1-44-50
Abstract
Neuroblastoma is the most frequent extracranial solid tumor of childhood. In 7 out of 10 cases, neuroblastoma is already disseminated at the time of diagnosis. Of the current nuclear medicine techniques, scintigraphy with methaiodobenzylguanidine, which is a 123I-labeled noradrenaline analog or (123I-MIBG), plays the most important role in the evaluation of neuroblastoma. Currently, a new PET-tracer, 18F-MFBG (18F-labeled benziguanidine analog), has emerged that can be used in the radionuclide diagnosis of neuroblastomas. Our clinical observations showed identical diagnostic efficiency to scintigraphy data with 123I-MIBG with significantly faster blood clearance than 123I-MIBG, which allows us to perform studies as early as 1 h after intravenous administration. In one case PET/CT with 18F-MIBG revealed additional tumor foci, which allowed to correct therapy, which is certainly of great importance in clinical practice.
About the Authors
A. S. Krylov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Alexander S. Krylov
24 Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
A. A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Akgul A. Odzharova
24 Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
P. E. Tulin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Pavel E. Tulin
24 Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
M. V. Rubanskaya
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Marina V. Rubanskaya
24 Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
D. I. Nevzorov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Denis I. Nevzorov
24 Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
N. I. Nesterova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Natalia I. Nesterova
24 Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
References
1. Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011;41(5):345-53. https://doi.org/10.1053/j.semnuclmed.2011.05.001.
2. Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and of 123I-MIBG: Clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987;15(4):170-7. https://doi.org/10.1002/mpo.2950150406.
3. Colavolpe C, Guedj E, Cammilleri S, et al. Utility of FDGPET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;51(6):828-31. https://doi.org/10.1002/pbc.21594.
4. Sharp SE, Shulkin BL, Gelfand MJ, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50(8):1237-43. https://doi.org/10.2967/jnumed.108.060467.
5. Taggart DR, Han MM, Yuach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and 18F-Ňuorodeoxyglucose positron emission tomography to evaluate response aŌer iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27(32):5343-9. https://doi.org/10.1200/JCO.2008.20.5732.
6. Huang SY, Bolch WE, Lee C, et al. Patient-specific dosimetry using pretherapy 124 Im-iodobenzylguanidine (124 I] mIBG) dynamic PET/CT imaging before 131ImIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015;17(2):284-94. https://doi.org/10.1007/s11307-014-0783-7.
7. Cistaro A, Yuartuccio N, Caobelli F, et al. 124 I-MIBG: a new promising positron-emiƫng radiopharmaceutical for the evaluation of neuroblastoma. Nuclear Med Rev. 2015;18(2):102-6. https://doi.org/10.5603/NMR.2015.0024.
8. Wartski M, Jehanno N, Michon J, et al. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma. Clin Nucl Med. 2015;40(12):969-70. https://doi.org/10.1097/RLU.0000000000000957.
9. Matsubara K, Watabe H, Kumakura Y, et al. Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for 18F FDOPA PET by a model with detailed dopamine pathway. Synapse. 2011;65(8):751-62. https://doi.org/10.1002/syn.20899.
10. Piccardo A, Lopci E, Foppiani L, et al. (18)F-DOPA PET/ CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma. Pediatr Radiol. 2014;44(3):355-61. https://doi.org/10.1007/s00247-013-2807-x.
11. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447-55. https://doi.org/10.1002/cncr.23469.
12. Gains JE, Aldridge MD, Mattoli MV, et al. 68Ga-DOTATATE and 123I-MIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: Implications for molecular radiotherapy. Nucl Med Commun 2020;41(11):1169-77. https://doi.org/10.1097/MNM.0000000000001265.
13. Telli T, Ergƺn EL, Salanci BV, et al. The complementary role of 68Ga-DOTATATE PET/CT in neuroblastoma. Clin Nucl Med. 2020;45(4):326-29. https://doi.org/10.1097/RLU.0000000000002961.
14. Nikolaeva EA, Krylov AS, Kasprshyk SM, et al. Comparison of scintigraphy with 123I-MIBG and 99mTc-tectrotyde in patients with tumors of a neurogenic nature. Russian Journal of Pediatric Hematology and Oncology. 2024;11(1):36-43. (In Russ.). https://doi.org/10.21682/2311-1267-2024-11-1-36-43.
15. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261(1):243-57. https://doi.org/10.1148/radiol.11101352.
16. Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45(11):2009-24. https://doi.org/10.1007/s00259-018-4070-8.
17. Zhang H, Huang R, Pillarsetty NVK, et al. Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging. 2014;41(2):322-32. https://doi.org/10.1007/s00259-013-2558-9.
18. Hu B, Vavere AL, Neumann KD, et al. A practical, automated synthesis of meta-18)FŇuorobenzylguanidine for clinical use. ACS Chem Neurosci. 2015;18(6):1870-9. https://doi.org/10.1021/acschemneuro.5b00202.
19. Samim F, Blom T, Poot AJ, et al. 18F mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50(4):1146-57. https://doi.org/10.1007/s00259-022-06063-6.
20. Pandit-Taskar N, Zanzonico P, Staton KD, et al. Biodistribution and dosimetry of 18F-MetaFluorobenzylguanidine: a first-inhuman PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59(1):147-53. https://doi.org/10.2967/jnumed.117.193169.
21.
Review
For citations:
Krylov A.S., Odzharova A.A., Tulin P.E., Rubanskaya M.V., Nevzorov D.I., Nesterova N.I. 18F-metafluorobenzylguanidine (18F-MFBG) PET/CT in Neuroblastoma. The First experience In Russia: Comparison with 123I-metaiodobenzylguanidine (123I-MIBG) Scintigraphy. Journal of oncology: diagnostic radiology and radiotherapy. 2025;8(1):44-50. (In Russ.) https://doi.org/10.37174/2587-7593-2025-8-1-44-50
Views:
245
Email this article 